OpenURL Connection Search

Select item for more details and to access through your institution.

The prevalence of patients suffering from chronic spontaneous urticaria, in whom omalizumab cannot be stopped even after six years.
Published in:
Frontiers in Allergy, 2024, p. 1, doi. 10.3389/falgy.2024.1464466
By:
- V., Schichter-Konfino;
- R., Mubariki;
- E., Toubi;
- Z., Vadasz
Publication type:
Article
The Reduction of Serum B-Lymphocyte Activating Factor levels following Quinacrine Add-On Therapy in Systemic Lupus Erythematosus.
Published in:
Scandinavian Journal of Immunology, 2006, v. 63, n. 4, p. 299, doi. 10.1111/j.1365-3083.2006.01737.x
By:
- Toubi, E.;
- Kessel, A.;
- Rosner, I.;
- Rozenbaum, M.;
- Paran, D.;
- Shoenfeld, Y.
Publication type:
Article
Antibodies against the VRT101 laminin epitope correlate with human SLE disease activity and can be removed by extracorporeal immunoadsorption.
Published in:
Rheumatology, 2007, v. 46, n. 9, p. 1433, doi. 10.1093/rheumatology/kem181
By:
- Amital, H.;
- Heilweil-Harel, M.;
- Ulmansky, R.;
- Harlev, M.;
- Toubi, E.;
- Hershko, A.;
- Naparstek, Y.
Publication type:
Article
Antibodies against the VRT101 laminin epitope correlate with human SLE disease activity and can be removed by extracorporeal immunoadsorption.
Published in:
Rheumatology, 2007, v. 46, n. 9, p. 1433, doi. 10.1093/rheumatology/kem181
By:
- H. Amital;
- M. Heilweil-Harel;
- R. Ulmansky;
- M. Harlev;
- E. Toubi;
- A. Hershko;
- Y. Naparstek
Publication type:
Article
Increased Spontaneous Apoptosis of CD4+CD25+ T Cells in Patients with Active Rheumatoid Arthritis Is Reduced by Infliximab.
Published in:
Annals of the New York Academy of Sciences, 2005, v. 1051, n. 1, p. 506, doi. 10.1196/annals.1361.095
By:
- TOUBI, E.;
- KESSEL, A.;
- MAHMUDOV, Z.;
- HALLAS, K.;
- ROZENBAUM, M.;
- ROSNER, I.
Publication type:
Article
The role of regulatory T cells in familial Mediterranean fever (FMF).
Published in:
Clinical Rheumatology, 2012, v. 31, n. 5, p. 885, doi. 10.1007/s10067-011-1935-7
By:
- Rimar, D.;
- Rosner, I.;
- Slobodin, G.;
- Boulman, N.;
- Toubi, E.;
- Kessel, A.;
- Peri, R.;
- Rozenbaum, M.
Publication type:
Article
Imbalance in B cell and T Follicular Helper Cell Subsets in Pulmonary Sarcoidosis.
Published in:
Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-020-57741-0
By:
- Kudryavtsev, I.;
- Serebriakova, M.;
- Starshinova, A.;
- Zinchenko, Y.;
- Basantsova, N.;
- Malkova, A.;
- Soprun, L.;
- Churilov, L. P.;
- Toubi, E.;
- Yablonskiy, P.;
- Shoenfeld, Y.
Publication type:
Article
Increased susceptibility of cord blood B lymphocytes to undergo spontaneous apoptosis.
Published in:
Clinical & Experimental Immunology, 2006, v. 145, n. 3, p. 563, doi. 10.1111/j.1365-2249.2006.03170.x
By:
- Kessel, A.;
- Yehudai, D.;
- Peri, R.;
- Pavlotzky, E.;
- Bamberger, E.;
- Tov, N.;
- Toubi, E.
Publication type:
Article
Peripheral B-cell CD5 expansion and CD81 overexpression and their association with disease severity and autoimmune markers in chronic hepatitis C virus infection.
Published in:
Clinical & Experimental Immunology, 2002, v. 128, n. 2, p. 353, doi. 10.1046/j.1365-2249.2002.01844.x
By:
- ZUCKERMAN, E;
- SLOBODIN, G;
- KESSEL, A;
- SABO, E;
- YESHURUN, D;
- HALAS, K;
- TOUBI, E
Publication type:
Article
The autoreactivity of B cells in hereditary angioedema due to C1 inhibitor deficiency.
Published in:
Clinical & Experimental Immunology, 2012, v. 167, n. 3, p. 422, doi. 10.1111/j.1365-2249.2011.04527.x
By:
- Kessel, A.;
- Peri, R.;
- Perricone, R.;
- Guarino, M. D.;
- Vadasz, Z.;
- Novak, R.;
- Haj, T.;
- Kivity, S.;
- Toubi, E.
Publication type:
Article
Treatment with glutamine is associated with down-regulation of Toll-like receptor-4 and myeloid differentiation factor 88 expression and decrease in intestinal mucosal injury caused by lipopolysaccharide endotoxaemia in a rat.
Published in:
Clinical & Experimental Immunology, 2008, v. 151, n. 2, p. 341, doi. 10.1111/j.1365-2249.2007.03571.x
By:
- Kessel, A.;
- Toubi, E.;
- Pavlotzky, E.;
- Mogilner, J.;
- Coran, A. G.;
- Lurie, M.;
- Karry, R.;
- Sukhotnik, I.
Publication type:
Article
Semaphorin 3A – a marker for disease activity and a potential putative disease-modifying treatment in systemic lupus erythematosus.
Published in:
Lupus, 2012, v. 21, n. 12, p. 1266, doi. 10.1177/0961203312456753
By:
- Vadasz, Z;
- Toubi, E
Publication type:
Article
The involvement of immune semaphorins and neuropilin-1 in lupus nephritis.
Published in:
Lupus, 2011, v. 20, n. 14, p. 1466, doi. 10.1177/0961203311417034
By:
- Vadasz, Z;
- Ben-Izhak, O;
- Bejar, J;
- Sabo, E;
- Kessel, A;
- Storch, S;
- Toubi, E
Publication type:
Article
Predictive and protective autoimmunity in cardiovascular diseases: is vaccination therapy a reality?
Published in:
Lupus, 2005, v. 14, n. 9, p. 665, doi. 10.1191/0961203305lu2196oa
By:
- Toubi, E.;
- Shoenfeld, Y.
Publication type:
Article
Quinacrine added to ongoing therapeutic regimens attenuates anticardiolipin antibody production in SLE.
Published in:
Lupus, 2003, v. 12, n. 4, p. 297, doi. 10.1191/0961203303lu319oa
By:
- Toubi, E;
- Kessel, A;
- Rosner, I;
- Rozenbaum, M;
- Lorber, M;
- Paran, D;
- Sabo, E;
- Golan, T D
Publication type:
Article
Intravenous cyclophosphamide in SLE.
Published in:
Lupus, 2000, v. 9, n. 6, p. 478, doi. 10.1191/096120300678828631
By:
- Toubi, E.;
- Kessel, A.
Publication type:
Article
The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients.
Published in:
Lupus, 2000, v. 9, n. 2, p. 92, doi. 10.1191/096120300678828082
By:
- Toubi, E.;
- Rosner, I.;
- Rozenbaum, M.;
- Kessel, A.;
- Gola&, T. D.
Publication type:
Article
Controversies and challenges in the management of chronic urticaria.
Published in:
Journal of the European Academy of Dermatology & Venereology, 2016, v. 30, p. 16, doi. 10.1111/jdv.13696
By:
- Staubach, P.;
- Zuberbier, T.;
- Vestergaard, C.;
- Siebenhaar, F.;
- Toubi, E.;
- Sussman, G.
Publication type:
Article
Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria.
Published in:
Journal of the European Academy of Dermatology & Venereology, 2016, v. 30, p. 25, doi. 10.1111/jdv.13697
By:
- Giménez‐Arnau, A. M.;
- Toubi, E.;
- Marsland, A. M.;
- Maurer, M.
Publication type:
Article
Controversies and challenges in the management of chronic urticaria.
Published in:
Journal of the European Academy of Dermatology & Venereology, 2016, v. 30, p. 16, doi. 10.1111/jdv.13696
By:
- Staubach, P.;
- Zuberbier, T.;
- Vestergaard, C.;
- Siebenhaar, F.;
- Toubi, E.;
- Sussman, G.
Publication type:
Article
Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria.
Published in:
Journal of the European Academy of Dermatology & Venereology, 2016, v. 30, p. 25, doi. 10.1111/jdv.13697
By:
- Giménez‐Arnau, A. M.;
- Toubi, E.;
- Marsland, A. M.;
- Maurer, M.
Publication type:
Article
An individualized diagnostic approach based on guidelines for chronic urticaria ( CU).
Published in:
Journal of the European Academy of Dermatology & Venereology, 2015, v. 29, p. 3, doi. 10.1111/jdv.13196
By:
- Giménez‐Arnau, A.M.;
- Grattan, C.;
- Zuberbier, T.;
- Toubi, E.
Publication type:
Article
Diagnostic dilemmas in chronic urticaria.
Published in:
Journal of the European Academy of Dermatology & Venereology, 2015, v. 29, p. 12, doi. 10.1111/jdv.13197
By:
- Toubi, E.;
- Grattan, C.;
- Zuberbier, T.
Publication type:
Article
Interleukin‐17 is a potential player and treatment target in severe chronic spontaneous urticaria.
Published in:
Clinical & Experimental Allergy, 2020, v. 50, n. 7, p. 799, doi. 10.1111/cea.13616
By:
- Sabag, D. A.;
- Matanes, L.;
- Bejar, J.;
- Sheffer, H.;
- Barzilai, A.;
- Church, M. K.;
- Toubi, E.;
- Maurer, M.;
- Vadasz, Z.
Publication type:
Article
Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study.
Published in:
Clinical & Experimental Allergy, 2012, v. 42, n. 6, p. 929, doi. 10.1111/j.1365-2222.2012.03984.x
By:
- Moldovan, D.;
- Reshef, A.;
- Fabiani, J.;
- Kivity, S.;
- Toubi, E.;
- Shlesinger, M.;
- Triggiani, M.;
- Montinaro, V.;
- Cillari, E.;
- Realdi, G.;
- Cancian, M.;
- Visscher, S.;
- Zanichelli, A.;
- Relan, A.;
- Cicardi, M.
Publication type:
Article
Definition, aims, and implementation of GA2 LEN Urticaria Centers of Reference and Excellence.
Published in:
Allergy, 2016, v. 71, n. 8, p. 1210, doi. 10.1111/all.12901
By:
- Maurer, M.;
- Metz, M.;
- Bindslev‐Jensen, C.;
- Bousquet, J.;
- Canonica, G. W.;
- Church, M. K.;
- Godse, K. V.;
- Grattan, C. E.;
- Hide, M.;
- Kocatürk, E.;
- Magerl, M.;
- Makris, M.;
- Meshkova, R.;
- Saini, S. S.;
- Sussman, G.;
- Toubi, E.;
- Zhao, Z.;
- Zuberbier, T.;
- Gimenez‐Arnau, A.
Publication type:
Article
Cyclosporine-A in severe chronic urticaria: the option for long-term therapy.
Published in:
Allergy, 2010, v. 65, n. 11, p. 1478, doi. 10.1111/j.1398-9995.2010.02419.x
By:
- Kessel, A.;
- Toubi, E.
Publication type:
Article
The bronchodilation test in seasonal vs perennial allergic rhinitis.
Published in:
2010
By:
- Kessel, A.;
- Toubi, E.
Publication type:
Letter
Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients.
Published in:
Allergy, 2004, v. 59, n. 8, p. 869, doi. 10.1111/j.1398-9995.2004.00473.x
By:
- Toubi, E.;
- Kessel, A.;
- Avshovich, N.;
- Bamberger, E.;
- Sabo, E.;
- Nasem, D.;
- Panasoff, J.
Publication type:
Article
Prolonged cyclosporin-A treatment for severe chronic urticaria.
Published in:
Allergy, 2003, v. 58, n. 6, p. 535, doi. 10.1034/j.1398-9995.2003.00151.x
By:
- Toubi, E.;
- Bamberger, E.;
- Kessel, A.
Publication type:
Article
Increased plasma levels of matrix metalloproteinase-9 are associated with the severity of chronic urticaria.
Published in:
Clinical & Experimental Allergy, 2005, v. 35, n. 2, p. 221, doi. 10.1111/j.1365-2222.2005.02168.x
By:
- Kessel, A.;
- Bishara, R.;
- Amital, A.;
- Bamberger, E.;
- Sabo, E.;
- Grushko, G.;
- Toubi, E.
Publication type:
Article
Follow-up after systemic adverse reactions of immunotherapy.
Published in:
Allergy, 1999, v. 54, n. 6, doi. 10.1034/j.1398-9995.1999.t01-1-00094.x
By:
- Toubi, E;
- Kessel, A;
- Blant, A;
- Golan, Td
Publication type:
Article
Low-dose cyclosporin A in the treatment of severe chronic idiopathic urticaria.
Published in:
Allergy, 1997, v. 52, n. 3, p. 312, doi. 10.1111/j.1398-9995.1997.tb00996.x
By:
- Toubi, E.;
- Blant, A.;
- Kessel, A.;
- Golan, T. D.
Publication type:
Article
INTERFERON-GAMMA-RELEASE ASSAY PREVENTS UNNECESSARY TUBERCULOSIS THERAPY.
Published in:
Israel Medical Association Journal, 2015, v. 17, n. 9, p. 594
By:
- Toubi, E.
Publication type:
Article
Rituximab: Beyond Simple B Cell Depletion.
Published in:
Clinical Reviews in Allergy & Immunology, 2008, v. 34, n. 1, p. 74, doi. 10.1007/s12016-008-8074-1
By:
- Kessel, A.;
- Rosner, I.;
- Toubi, E.
Publication type:
Article
The role of increased T helper cell 2 cytokine expression in skin weals of chronic spontaneous urticaria: are they always activating cytokines?
Published in:
British Journal of Dermatology, 2015, v. 172, n. 5, p. 1185, doi. 10.1111/bjd.13784
By:
- Vadasz, Z.;
- Toubi, E.
Publication type:
Article

Found: 36

The prevalence of patients suffering from chronic spontaneous urticaria, in whom omalizumab cannot be stopped even after six years.

The Reduction of Serum B-Lymphocyte Activating Factor levels following Quinacrine Add-On Therapy in Systemic Lupus Erythematosus.

Antibodies against the VRT101 laminin epitope correlate with human SLE disease activity and can be removed by extracorporeal immunoadsorption.

Antibodies against the VRT101 laminin epitope correlate with human SLE disease activity and can be removed by extracorporeal immunoadsorption.

Increased Spontaneous Apoptosis of CD4<sup>+</sup>CD25<sup>+</sup> T Cells in Patients with Active Rheumatoid Arthritis Is Reduced by Infliximab.

The role of regulatory T cells in familial Mediterranean fever (FMF).

Imbalance in B cell and T Follicular Helper Cell Subsets in Pulmonary Sarcoidosis.

Increased susceptibility of cord blood B lymphocytes to undergo spontaneous apoptosis.

Peripheral B-cell CD5 expansion and CD81 overexpression and their association with disease severity and autoimmune markers in chronic hepatitis C virus infection.

The autoreactivity of B cells in hereditary angioedema due to C1 inhibitor deficiency.

Treatment with glutamine is associated with down-regulation of Toll-like receptor-4 and myeloid differentiation factor 88 expression and decrease in intestinal mucosal injury caused by lipopolysaccharide endotoxaemia in a rat.

Semaphorin 3A – a marker for disease activity and a potential putative disease-modifying treatment in systemic lupus erythematosus.

The involvement of immune semaphorins and neuropilin-1 in lupus nephritis.

Predictive and protective autoimmunity in cardiovascular diseases: is vaccination therapy a reality?

Quinacrine added to ongoing therapeutic regimens attenuates anticardiolipin antibody production in SLE.

Intravenous cyclophosphamide in SLE.

The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients.

Controversies and challenges in the management of chronic urticaria.

Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria.

Controversies and challenges in the management of chronic urticaria.

Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria.

An individualized diagnostic approach based on guidelines for chronic urticaria ( CU).

Diagnostic dilemmas in chronic urticaria.

Interleukin‐17 is a potential player and treatment target in severe chronic spontaneous urticaria.

Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study.

Definition, aims, and implementation of GA<sup>2</sup> LEN Urticaria Centers of Reference and Excellence.

Cyclosporine-A in severe chronic urticaria: the option for long-term therapy.

The bronchodilation test in seasonal vs perennial allergic rhinitis.

Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients.

Prolonged cyclosporin-A treatment for severe chronic urticaria.

Increased plasma levels of matrix metalloproteinase-9 are associated with the severity of chronic urticaria.

Follow-up after systemic adverse reactions of immunotherapy.

Low-dose cyclosporin A in the treatment of severe chronic idiopathic urticaria.

INTERFERON-GAMMA-RELEASE ASSAY PREVENTS UNNECESSARY TUBERCULOSIS THERAPY.

Rituximab: Beyond Simple B Cell Depletion.

The role of increased T helper cell 2 cytokine expression in skin weals of chronic spontaneous urticaria: are they always activating cytokines?